Literature DB >> 28529997

PD-1 and CTLA4: Two checkpoints, one pathway?

Lucy S K Walker1.   

Abstract

Entities:  

Year:  2017        PMID： 28529997      PMCID： PMC5436606          DOI： 10.1126/sciimmunol.aan3864

Source DB:  PubMed          Journal:  Sci Immunol        ISSN： 2470-9468


× No keyword cloud information.
  10 in total

1.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

2.  Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation.

Authors:  Xuguang Tai; Francois Van Laethem; Arlene H Sharpe; Alfred Singer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-16       Impact factor: 11.205

3.  Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.

Authors:  S Alice Long; Jerill Thorpe; Hannah A DeBerg; Vivian Gersuk; James Eddy; Kristina M Harris; Mario Ehlers; Kevan C Herold; Gerald T Nepom; Peter S Linsley
Journal:  Sci Immunol       Date:  2016-11-18

4.  Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model.

Authors:  Baihao Zhang; Shunsuke Chikuma; Shohei Hori; Sidonia Fagarasan; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-07       Impact factor: 11.205

5.  The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.

Authors:  Lucy S K Walker; David M Sansom
Journal:  Nat Rev Immunol       Date:  2011-11-25       Impact factor: 53.106

6.  Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.

Authors:  Alice O Kamphorst; Andreas Wieland; Tahseen Nasti; Shu Yang; Ruan Zhang; Daniel L Barber; Bogumila T Konieczny; Candace Z Daugherty; Lydia Koenig; Ke Yu; Gabriel L Sica; Arlene H Sharpe; Gordon J Freeman; Bruce R Blazar; Laurence A Turka; Taofeek K Owonikoko; Rathi N Pillai; Suresh S Ramalingam; Koichi Araki; Rafi Ahmed
Journal:  Science       Date:  2017-03-09       Impact factor: 47.728

7.  T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

Authors:  Enfu Hui; Jeanne Cheung; Jing Zhu; Xiaolei Su; Marcus J Taylor; Heidi A Wallweber; Dibyendu K Sasmal; Jun Huang; Jeong M Kim; Ira Mellman; Ronald D Vale
Journal:  Science       Date:  2017-03-09       Impact factor: 47.728

8.  The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness.

Authors:  Tuoqi Wu; Yun Ji; E Ashley Moseman; Haifeng C Xu; Monica Manglani; Martha Kirby; Stacie M Anderson; Robin Handon; Elizabeth Kenyon; Abdel Elkahloun; Weiwei Wu; Philipp A Lang; Luca Gattinoni; Dorian B McGavern; Pamela L Schwartzberg
Journal:  Sci Immunol       Date:  2016-12-09

9.  Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.

Authors:  Se Jin Im; Masao Hashimoto; Michael Y Gerner; Junghwa Lee; Haydn T Kissick; Matheus C Burger; Qiang Shan; J Scott Hale; Judong Lee; Tahseen H Nasti; Arlene H Sharpe; Gordon J Freeman; Ronald N Germain; Helder I Nakaya; Hai-Hui Xue; Rafi Ahmed
Journal:  Nature       Date:  2016-08-02       Impact factor: 49.962

10.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307
  10 in total
  9 in total

1.  T Cell Reprogramming Against Cancer.

Authors:  Samuel G Katz; Peter M Rabinovich
Journal:  Methods Mol Biol       Date:  2020

2.  Force-dependent trans-endocytosis by breast cancer cells depletes costimulatory receptor CD80 and attenuates T cell activation.

Authors:  Seungman Park; Yu Shi; Byoung Choul Kim; Myung Hyun Jo; Leilani O Cruz; Zheming Gou; Taekjip Ha; Li-Fan Lu; Daniel H Reich; Yun Chen
Journal:  Biosens Bioelectron       Date:  2020-06-17       Impact factor: 10.618

3.  CD5 signalosome coordinates antagonist TCR signals to control the generation of Treg cells induced by foreign antigens.

Authors:  Gaëtan Blaize; Hélène Daniels-Treffandier; Meryem Aloulou; Nelly Rouquié; Cui Yang; Marlène Marcellin; Mylène Gador; Mehdi Benamar; Mariette Ducatez; Ki-Duk Song; Odile Burlet-Schiltz; Abdelhadi Saoudi; Paul E Love; Nicolas Fazilleau; Anne Gonzalez de Peredo; Renaud Lesourne
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-20       Impact factor: 11.205

Review 4.  Melanoma and Immune Checkpoint Inhibitors.

Authors:  Masutaka Furue; Takamichi Ito; Naoko Wada; Maiko Wada; Takafumi Kadono; Hiroshi Uchi
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

5.  Using Machine Learning Modeling to Explore New Immune-Related Prognostic Markers in Non-Small Cell Lung Cancer.

Authors:  Jiasheng Xu; Han Nie; Jiarui He; Xinlu Wang; Kaili Liao; Luxia Tu; Zhenfang Xiong
Journal:  Front Oncol       Date:  2020-10-30       Impact factor: 6.244

6.  Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma.

Authors:  Jonathan E Lu; Jessica R Chang; Jesse L Berry; Gino K In; Sandy Zhang-Nunes
Journal:  Int Ophthalmol Clin       Date:  2020

Review 7.  Targeting co-stimulatory molecules in autoimmune disease.

Authors:  Natalie M Edner; Gianluca Carlesso; James S Rush; Lucy S K Walker
Journal:  Nat Rev Drug Discov       Date:  2020-09-16       Impact factor: 112.288

8.  Exhausted CD4+ T Cells during Malaria Exhibit Reduced mTORc1 Activity Correlated with Loss of T-bet Expression.

Authors:  Ana Villegas-Mendez; Garima Khandelwal; Lucy M McGowan; Rebecca S Dookie; Michael J Haley; Charlotte George; David Sims; Graham M Lord; Linda V Sinclair; Richard G Jenner; Kevin N Couper
Journal:  J Immunol       Date:  2020-08-17       Impact factor: 5.422

9.  Regulation of the immune tolerance system determines the susceptibility to HLA-mediated abacavir-induced skin toxicity.

Authors:  Takeshi Susukida; Saki Kuwahara; Binbin Song; Akira Kazaoka; Shigeki Aoki; Kousei Ito
Journal:  Commun Biol       Date:  2021-09-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.